VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation
暂无分享,去创建一个
R. Jain | D. Fukumura | S. Chae | Michelle R. Dawson | D. Duda | M. Dawson | Sung-suk Chae | D. Duda
[1] R. Jain,et al. VEGFR1-activity-independent metastasis formation , 2009, Nature.
[2] R. Jain,et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[4] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[5] J. Erler,et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.
[6] Christian Fischer,et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.
[7] Roger R. Gomis,et al. TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.
[8] D. Nolan,et al. Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.
[9] M. Giacca,et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.
[10] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[11] D. Hicklin,et al. Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer , 2006, Clinical Cancer Research.
[12] R. Jain,et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. , 2006, Blood.
[13] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[14] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[15] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[16] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[17] M. Shibuya,et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.
[18] O. Nishimura,et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor , 2001, Nature.
[19] T. Noda,et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] N. Ferrara,et al. Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.
[21] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] N. Wolmark,et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[24] L. Coussens,et al. Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.
[25] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[26] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.